PACIFIC BIOMETRICS REPORTS 233% REVENUE GROWTH FOR FISCAL 2006.

Pacific Biometrics, Inc. (OTCBB: PBME; "PBI"), Seattle, a leading provider of specialized central laboratory and contract research services, released financial results for fiscal 2006. Revenues for the year ended June 30, 2006 increased 233% to $10,750,023 from $3,230,374 for the comparable period last year. Operating income increased to $1,846,445 from a loss of $2,158,911 for the same period last year. EBITDA income increased to $1,723,806 or $0.11 per fully diluted share, compared to a loss of $2,249,486 or $0.18 for fiscal 2005. The company achieved a net income for the year of $179,103 or $0.01 per fully diluted share, compared with a net loss of $2,992,960, or $0.24 per fully diluted share, for the same period during fiscal 2005.

Revenue for the fourth quarter ended June 30, 2006 increased 264% to $2,692,829 from $738,848 during the comparable period last year. Operating income increased to $240,968 from a loss of $870,355 for the same period last year.

"2006 has proven to be the best year ever recorded in PBI's history," commented Ron Helm, chairman and CEO of Pacific Biometrics. "Increased business development efforts and a reputation as the premier laboratory across multiple categories of biomarkers have driven record revenues, and we anticipate this trend to continue in fiscal 2007. Revenues for 2006 more than tripled those for 2005, we have positive EBITDA income of $1.724M, and as of June 30, 2006 we had $5.5M in cash and cash equivalents on the balance sheet. As a result of these substantial improvements in PBI's financial performance, the company's independent auditors have removed the "going concern" clause from our Form 10-KSB annual report. Furthermore, we recorded a net profit of $179,103 despite non- cash expenses associated with amortization, warrants and deferred financing costs. PBI is now operationally profitable and we are confident that this financial trend will continue." Helm continued: "We announced clinical study contracts with some of the largest pharmaceutical and biotech companies in the world this year, which has substantially added to our backlog for fiscal 2007 and 2008. PBI will continue to focus on providing quality specialty laboratory services in its core areas, including cardiovascular disease, diabetes, metabolic syndrome, osteoporosis, and arthritis. We believe the demand for our expertise in clinical development studies for our clients will continue to be a significant driver for future growth." For additional information, see Pacific Biometrics' annual report filed with the SEC on Form 10-KSB for the fiscal year ended June 30, 2006 and the quarterly reports filed with the SEC on Form 10-QSB for the fiscal quarters ended September 30, 2005, December 31, 2005, and March 31, 2006. About Pacific Biometrics, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.

For more information, visit http://www.pacbio.com or call 206/298-0068.